Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation

Transplant International : Official Journal of the European Society for Organ Transplantation
Marcus D SäemannGerhard J Zlabinger

Abstract

Current immunosuppressive therapy in clinical organ transplantation is based on drugs that suppress various functions of immunocompetent cells but still affect cells and organ compartments other than the immune system. Hence, these drugs have considerable side effects which lead to increased morbidity and reduced life-quality of transplant recipients. A major step forward in the rationale design of clinical immunosuppression resides in the elucidation of molecular targets that play a critical role specifically within the immune system. Recently, Janus kinase 3 (JAK3) has been identified as such a molecule. Genetic absence or ablation of this tyrosine kinase is associated with defective T-cell immunity that results in severe combined immunodeficiency (SCID) without apparent changes in other organ systems. Furthermore, pharmacological inhibition has significantly prolonged allograft survival in several experimental models of organ transplantation. The present review provides an overview of the emerging role of JAK3 in the immune system and the development of JAK3-inhibiting drugs. The potential clinical application of JAK3 inhibitors in organ transplantations is discussed in the light of a recent series of successful kidney trans...Continue Reading

References

Jan 20, 1997·The Journal of Experimental Medicine·K SaijoT Saito
Apr 11, 1997·The Journal of Biological Chemistry·A González-GarcíaA C Carrera
Aug 1, 1997·Current Opinion in Immunology·D C Thomis, L J Berg
Feb 7, 1998·The Journal of Clinical Investigation·R CiubotariuN Suciu-Foca
Jun 10, 1998·Journal of Leukocyte Biology·A M BairdL J Berg
Oct 31, 1998·Immunological Reviews·N Suciu-FocaR Cortesini
Feb 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·H H LeeG Cheng
Jan 5, 2000·The Journal of Clinical Investigation·B J Druker, N B Lydon
Jan 21, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·X C LiT B Strom
Jul 6, 2000·Immunopharmacology·A C Allison, E M Eugui
Aug 2, 2000·Proceedings of the National Academy of Sciences of the United States of America·M BianchiL B Ivashkiv
Sep 28, 2000·Current Opinion in Immunology·C DambrinR E Morris
Jan 3, 2001·Molecular and Cellular Biology·R WenJ L Cleveland
Mar 10, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·F BehbodR A Kirken
Jul 5, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·M Behrend
Oct 26, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·R MooreH Valantine
Dec 26, 2001·Transplantation Proceedings·R A Kirken
Dec 26, 2001·Transplantation Proceedings·S M StepkowskiR A Kirken
Dec 26, 2001·Transplantation Proceedings·S M StepkowskiR A Kirken
Jan 10, 2002·Genes and Immunity·D M FruchtF Candotti
Feb 5, 2002·Expert Opinion on Pharmacotherapy·B D Kahan
Nov 15, 2002·Transplantation Proceedings·A C Allison
Feb 27, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Bertram L KasiskeArthur J Matas
Mar 11, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·François Van LaethemOberdan Leo
Apr 23, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Marina Cetkovic-CvrljeFatih M Uckun
Jun 24, 2003·Journal of the American Society of Nephrology : JASN·Flavio Vincenti
Oct 4, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Marcus D SäemannGerhard J Zlabinger
Oct 8, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Fariba BehbodRobert A Kirken
Nov 1, 2003·Science·Paul S ChangelianDominic C Borie
Dec 12, 2003·The New England Journal of Medicine·Brian J NankivellJeremy R Chapman
Dec 12, 2003·Nature Reviews. Immunology·Ke Shuai, Bin Liu

❮ Previous
Next ❯

Citations

Mar 7, 2009·Expert Opinion on Emerging Drugs·Kiran K Khush, Hannah A Valantine
May 1, 2010·International Immunopharmacology·Rama MalaviyaRavi Malaviya
Jul 10, 2007·Seminars in Nephrology·Julie M Yabu, Flavio Vincenti
Oct 3, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·F Vincenti, A D Kirk
Mar 19, 2008·Biochemical and Biophysical Research Communications·Xiaonan ZhangZhenghong Yuan
Mar 20, 2009·Transplantation·Jeffrey B VelottaSonja Schrepfer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Recent Patents on Inflammation & Allergy Drug Discovery
Zuquan XiongHuifang Chen
Trends in Pharmacological Sciences
Anastassios C Papageorgiou, Linnea E K Wikman
Current Opinion in Investigational Drugs
Dominic C BoriePaul Changelian
© 2021 Meta ULC. All rights reserved